Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

The Board of Directors (the “Board”) of Caladrius Biosciences, Inc. (the “Company”), in accordance with the terms of the Company’s amended and restated certificate of incorporation, has determined to move one of the Company’s directors from Class III into Class I to achieve more equally balanced membership classes. Peter G. Traber, MD, a Class III director, was to serve on the Board under his current term until expiration at the annual meeting of stockholders to be held in 2019. Dr. Traber agreed to resign as a Class III director, after which he was immediately reappointed to the Board as a Class I director for a term that will expire at the Company’s 2017 annual meeting of stockholders. The resignation and reappointment of Dr. Traber was effected solely to satisfy certain legal requirements under the Delaware General Corporation Law and the Company’s amended and restated certificate of incorporation, that the Company seek to balance its Board classes as much as practicable. For all other purposes, Dr. Traber’s service on the Board is deemed to have continued uninterrupted. The Board now consists of three Class I directors whose term will expire at the annual meeting of stockholders to be held in 2017; two Class II directors whose term will expire at the annual meeting of stockholders to be held in 2018; and two Class III directors whose term will expire at the annual meeting of stockholders to be held in 2019.

About CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS)

Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company’s T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases.

CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Recent Trading Information

CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) closed its last trading session down -0.16 at 4.93 with 56,049 shares trading hands.